Sobi® (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study (NCT06694701), evaluating Gamifant® (emapalumab) in patients with interferon-gamma (IFNγ)-driven sepsis (IDS), ...
Sobi presents positive results from EMBRACE phase 2a study of emapalumab in interferon-gamma-driven sepsis at ISICEM: Stockholm Thursday, March 19, 2026, 12:00 Hrs [IST] Sobi, a g ...
Background Concomitant metabolic dysfunction-associated steatotic liver disease (MASLD) is prevalent in patients with chronic hepatitis B (CHB), yet its impact on liver-related outcomes remains ...
Detailed price information for Oncolytics Biotech Inc (ONCY-Q) from The Globe and Mail including charting and trades.
Background High serum levels of interleukin 6 (IL-6) predict poor prognosis in intrahepatic cholangiocarcinoma (iCCA), a malignancy that often develops in a chronically inflamed milieu . Here, tumour ...
Sepsis remains a major challenge in modern medicine, claiming millions of lives each year. For decades, clinical management has largely focused on suppressing excessive inflammation. Yet many patients ...
Morning Overview on MSN
Scientists find 'molecular switch' that supercharges natural immunity
A team led by researchers at the University of Cologne has identified a protein called ANKIB1 that acts as a volume dial for the body’s frontline immune defenses, controlling how strongly cells ...
Restoring the gut microbiota through fecal microbiota transplantation reversed these effects. The treatment replenished CX3CR1-positive NK cells, reduced lung damage, and improved survival. Targeted ...
MedPage Today on MSN
Exercise to Thwart 'Chemo Brain' Shows Promise in Randomized Trial
Significantly less cancer-related cognitive impairment, mental fatigue after chemotherapy ...
In an in vivo mouse model, HotSpot's IRF5 inhibitors demonstrated dose-dependent inhibition of cytokines and mRNA response, as well as dose-dependent down-regulation of interferon and IRF5-driven gene ...
Manage your stage 3 ET diagnosis with this guide on high-risk treatments, side effects and new NCCN-preferred options to empower your next visit. While essential thrombocythemia (ET) is classified as ...
Early GO decision reached in CAPTIVATE ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results